Repligen Corporation (RGEN)
NEUTRALFundamental
59
मूल्य
$181.84
मार्केट कैप
$10.22B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$785M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$42M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$94M
कुल इक्विटी
$2.11B
कुल देनदारियाँ
$844M
Current Ratio
9.05
Interest Coverage
2.92
Debt/EBITDA
5.16
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$129.68
वर्तमान मूल्य
$181.84
Margin of Safety
-40.2%
Fair Value सीमा
$84.29 - $175.07
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
245.43
ROE
2.3%
P/B Ratio
4.85
P/FCF
91.55
Gross Margin
53.5%
ROIC
1.8%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
1.8%
WACC
10.0%
ROIC − WACC
-8.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (17)
- EPS shows upward trend
- Price CAGR 19.38%
- Gross Margin 53.5%
- Debt/Equity ratio
- Operating Margin 8.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 15.1%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 14.2%
- Earnings Quality (OCF/NI) 3.25
- Net Margin Trend 5.3% vs -2.1%
- Piotroski F-Score 7/9
फेल (8)
- ROIC 1.8%
- P/FCF 91.55
- P/B Ratio 4.85
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.0%
- Share Dilution 2.5%
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Olivier Loeillot | President, CEO & Director | 55 |
| Mr. Jason K. Garland | CFO & Chief Compliance Officer | 51 |
| Mr. Anthony J. Hunt | Advisor | 61 |
| Mr. Ralf Kuriyel | Senior Vice President of Research & Development | 67 |
| Mr. Brian Douglass | Senior VP & Chief Product Officer | 50 |
| Ms. Violetta Hughes | Chief Accounting Officer | 52 |
| Ms. Heather Ems | Chief Information Officer | - |
| Mr. Jacob K. Johnson C.F.A. | Vice President of Investor Relations | - |
| Mr. George A Scott Jr., J.D., M.B.A. | Senior VP & General Counsel | - |
| Mr. Neil Whitfield | Senior Vice President of Sales | - |
Audit जोखिम
10
बोर्ड जोखिम
4
मुआवजा जोखिम
4
शेयरधारक अधिकार जोखिम
1
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for RGEN, sourced from Markets Gazette.
- 2/24/2026NEUTRALRepligen (RGEN) Q4 2025 Earnings Call Transcript
Markets Gazette reports that the transcript for Repligen Corporation's (RGEN) Q4 2025 earnings call is now available. While specific details are not disclosed here, investors and analysts eagerly await an in-depth review of this document. Earnings call transcripts are crucial for understanding past financial performance, future projections, and corporate strategies. Market participants will be looking for insights into revenues, margins, product pipeline, and management's commentary regarding the life sciences sector outlook. The availability of such information is a standard event in the financial calendar, but its market impact will entirely depend on the data and statements contained within, which will guide future investment decisions.
via Markets Gazette